FDA and EPA Advance Plans to Phase Out Animal Testing in Favor of Human-Relevant Methods

New policies under the Trump administration aim to modernize drug and chemical testing with AI and lab-grown organ models, reducing costs and animal use.

The FDA announced a roadmap to phase out animal testing for monoclonal antibody therapies, replacing it with advanced human-relevant methods like AI modeling and organoid testing.
The Environmental Protection Agency (EPA) reinstated its commitment to reduce mammalian testing by 30% by 2025 and eliminate it entirely by 2035.
FDA Commissioner Martin Makary emphasized that the shift will improve drug safety, accelerate treatment approvals, and lower research and development costs.
Animal rights organization PETA praised the initiative, calling it a significant step toward ending animal testing and embracing modern scientific approaches.
The Trump administration's efforts build on the FDA Modernization Act 2.0 from 2023, signaling a broader regulatory and ethical commitment to innovation in drug and chemical testing.